Challice L Bonifant

Title: Challice L Bonifant: Innovator in Chimeric Antigen Receptors

Introduction

Challice L Bonifant is a notable inventor based in Towson, MD (US). He has made significant contributions to the field of cancer treatment through his innovative work on chimeric antigen receptors (CARs). With a total of 2 patents, Bonifant's research focuses on targeting abnormal glycobiology to enhance cancer therapies.

Latest Patents

Bonifant's latest patents include groundbreaking advancements in chimeric antigen receptors. One of his patents describes a CAR polypeptide that features an antigen binding domain comprising an extracellular lectin. This lectin specifically binds to glycoproteins expressed on the surface of target cells. The patent also details engineered lymphocytes that express the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods for treating cancer.

Career Highlights

Challice L Bonifant is affiliated with the University of Michigan, where he continues to advance his research in the field of immunotherapy. His work has garnered attention for its potential to improve cancer treatment outcomes.

Collaborations

Bonifant collaborates with esteemed colleagues such as Alnawaz Rehemtulla and David M Markovitz. Their combined expertise contributes to the innovative research being conducted in the realm of chimeric antigen receptors.

Conclusion

Challice L Bonifant is a pioneering inventor whose work on chimeric antigen receptors is paving the way for new cancer therapies. His contributions to the field are significant and hold promise for future advancements in medical science.